Literature DB >> 24644022

Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.

Laurent Chiche1, Noémie Jourde-Chiche, Elizabeth Whalen, Scott Presnell, Vivian Gersuk, Kristen Dang, Esperanza Anguiano, Charlie Quinn, Stéphane Burtey, Yvon Berland, Gilles Kaplanski, Jean-Robert Harle, Virginia Pascual, Damien Chaussabel.   

Abstract

OBJECTIVE: The role of interferon-α (IFNα) in the pathogenesis of systemic lupus erythematosus (SLE) is strongly supported by gene expression studies. The aim of this study was to improve characterization of the blood IFN signature in adult SLE patients.
METHODS: Consecutive patients were enrolled and followed up prospectively. Microarray data were generated using Illumina BeadChips. A modular transcriptional repertoire was used as a framework for the analysis.
RESULTS: Our repertoire of 260 modules, which consisted of coclustered gene sets, included 3 IFN-annotated modules (M1.2, M3.4, and M5.12) that were strongly up-regulated in SLE patients. A modular IFN signature was observed in 54 of 62 patients (87%) or 131 of all 157 samples (83%). The IFN signature was more complex than expected, with each module displaying a distinct activation threshold (M1.2 < M3.4 < M5.12), thus providing a modular score by which to stratify SLE patients based on the presence of 0, 1, 2, or 3 active IFN modules. A similar gradient in modular IFN signature was observed within patients with clinically quiescent disease, for whom moderate/strong modular scores (2 or 3 active IFN modules) were associated with higher anti-double-stranded DNA titers and lower lymphocyte counts than those in patients with absent/mild modular scores (0 or 1 active IFN modules). Longitudinal analyses revealed both stable (M1.2) and variable (M3.4 and M5.12) components of modular IFN signature over time in single patients. Interestingly, mining of other data sets suggested that M3.4 and M5.12 could also be driven by IFNβ and IFNγ.
CONCLUSION: Modular repertoire analysis reveals complex IFN signatures in SLE, which are not restricted to the previous IFNα signature, but which also involve IFNβ and IFNγ.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24644022      PMCID: PMC4157826          DOI: 10.1002/art.38628

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  48 in total

1.  Classification and definition of major flares in SLE clinical trials.

Authors:  M Petri; J Buyon; M Kim
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.

Authors:  Robert Bissonnette; Kim Papp; Catherine Maari; Yihong Yao; Gabriel Robbie; Wendy I White; Chenxiong Le; Barbara White
Journal:  J Am Acad Dermatol       Date:  2010-03       Impact factor: 11.527

3.  Systematic identification of type I and type II interferon-induced antiviral factors.

Authors:  Su-Yang Liu; David Jesse Sanchez; Roghiyh Aliyari; Sun Lu; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

4.  Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state.

Authors:  Kai A Kropp; Kevin A Robertson; Garwin Sing; Sara Rodriguez-Martin; Mathieu Blanc; Paul Lacaze; Muhamad F B Noor Hassim; Mizanur R Khondoker; Andreas Busche; Paul Dickinson; Thorsten Forster; Birgit Strobl; Mathias Mueller; Stipan Jonjic; Ana Angulo; Peter Ghazal
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

5.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

6.  Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus.

Authors:  M Nikpour; A A Dempsey; M B Urowitz; D D Gladman; D A Barnes
Journal:  Ann Rheum Dis       Date:  2007-12-06       Impact factor: 19.103

7.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.

Authors:  Damien Chaussabel; Charles Quinn; Jing Shen; Pinakeen Patel; Casey Glaser; Nicole Baldwin; Dorothee Stichweh; Derek Blankenship; Lei Li; Indira Munagala; Lynda Bennett; Florence Allantaz; Asuncion Mejias; Monica Ardura; Ellen Kaizer; Laurence Monnet; Windy Allman; Henry Randall; Diane Johnson; Aimee Lanier; Marilynn Punaro; Knut M Wittkowski; Perrin White; Joseph Fay; Goran Klintmalm; Octavio Ramilo; A Karolina Palucka; Jacques Banchereau; Virginia Pascual
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

8.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

9.  Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells.

Authors:  Dhivya Arasappan; Weida Tong; Padmaja Mummaneni; Hong Fang; Shashi Amur
Journal:  BMC Med       Date:  2011-05-30       Impact factor: 8.775

10.  Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Authors:  Michelle Petri; Daniel J Wallace; Alberto Spindler; Vishala Chindalore; Kenneth Kalunian; Eduardo Mysler; C Michael Neuwelt; Gabriel Robbie; Wendy I White; Brandon W Higgs; Yihong Yao; Liangwei Wang; Dominique Ethgen; Warren Greth
Journal:  Arthritis Rheum       Date:  2013-04
View more
  132 in total

1.  Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block.

Authors:  Robert M Clancy; Marc Halushka; Sara E Rasmussen; Tenzin Lhakhang; Miao Chang; Jill P Buyon
Journal:  J Immunol       Date:  2018-12-05       Impact factor: 5.422

2.  Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Authors:  Arna Katewa; Yugang Wang; Jason A Hackney; Tao Huang; Eric Suto; Nandhini Ramamoorthi; Cary D Austin; Meire Bremer; Jacob Zhi Chen; James J Crawford; Kevin S Currie; Peter Blomgren; Jason DeVoss; Julie A DiPaolo; Jonathan Hau; Adam Johnson; Justin Lesch; Laura E DeForge; Zhonghua Lin; Marya Liimatta; Joseph W Lubach; Sami McVay; Zora Modrusan; Allen Nguyen; Chungkee Poon; Jianyong Wang; Lichuan Liu; Wyne P Lee; Harvey Wong; Wendy B Young; Michael J Townsend; Karin Reif
Journal:  JCI Insight       Date:  2017-04-06

Review 3.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

4.  Foxo3 Promotes Apoptosis of B Cell Receptor-Stimulated Immature B Cells, Thus Limiting the Window for Receptor Editing.

Authors:  Kristina Ottens; Rochelle M Hinman; Evan Barrios; Brian Skaug; Laurie S Davis; Quan-Zhen Li; Diego H Castrillon; Anne B Satterthwaite
Journal:  J Immunol       Date:  2018-06-27       Impact factor: 5.422

Review 5.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

6.  IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE.

Authors:  Dan Li; Bharati Matta; Su Song; Victoria Nelson; Kirsten Diggins; Kim R Simpfendorfer; Peter K Gregersen; Peter Linsley; Betsy J Barnes
Journal:  JCI Insight       Date:  2020-01-30

7.  A vision and a prescription for big data-enabled medicine.

Authors:  Damien Chaussabel; Bali Pulendran
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

8.  MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease.

Authors:  Jaclyn N Taroni; Peter C Grayson; Qiwen Hu; Sean Eddy; Matthias Kretzler; Peter A Merkel; Casey S Greene
Journal:  Cell Syst       Date:  2019-05-22       Impact factor: 10.304

Review 9.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 10.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.